Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

Donald A. Bergstrom net worth and biography

Donald Bergstrom Biography and Net Worth

Insider of Relay Therapeutics

Don Bergstrom oversees Relay’s research and development efforts and shaping the Company’s portfolio of transformative medicines based on an understanding of protein motion. Prior to Relay, Don was chief medical officer at Mersana Therapeutics, where he led the advancement of two products based on Mersana’s proprietary antibody-drug conjugate platform through non-clinical development and into Phase 1 clinical trials. Prior to Mersana, he was global head of translational and experimental medicine at Sanofi Oncology. Prior to Sanofi, Don held roles of increasing responsibility at Merck Research Laboratories, culminating in his role as oncology franchise lead, experimental medicine.

Don holds an M.D. from the University of Washington, Seattle and a Ph.D. from the Fred Hutchinson Cancer Research Center, where he also completed post-doctoral training. He was a resident in clinical pathology at the University of Washington.

What is Donald A. Bergstrom's net worth?: The estimated net worth of Donald A. Bergstrom is at least $3.62 million as of March 27th, 2024. Dr. Bergstrom owns 530,113 shares of Relay Therapeutics stock worth more than $3,620,672 as of April 16th. This net worth estimate does not reflect any other assets that Dr. Bergstrom may own. Additionally, Dr. Bergstrom receives an annual salary of $711,250.00 as Insider at Relay Therapeutics. Learn More about Donald A. Bergstrom's net worth.
How old is Donald A. Bergstrom?: Dr. Bergstrom is currently 52 years old. There are 4 older executives and no younger executives at Relay Therapeutics. The oldest executive at Relay Therapeutics is Dr. Mark Murcko Ph.D., Co-Founder & Director, who is 64 years old. Learn More on Donald A. Bergstrom's age.
What is Donald A. Bergstrom's salary?: As the Insider of Relay Therapeutics, Inc., Dr. Bergstrom earns $711,250.00 per year. The highest earning executive at Relay Therapeutics is Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS, CEO, President & Director, who commands a salary of $1,030,000.00 per year. Learn More on Donald A. Bergstrom's salary.
How do I contact Donald A. Bergstrom?: The corporate mailing address for Dr. Bergstrom and other Relay Therapeutics executives is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. Relay Therapeutics can also be reached via phone at 617-370-8837 and via email at [email protected]. Learn More on Donald A. Bergstrom's contact information.
Has Donald A. Bergstrom been buying or selling shares of Relay Therapeutics?: Donald A. Bergstrom has not been actively trading shares of Relay Therapeutics during the last ninety days. Most recently, Donald A. Bergstrom sold 765 shares of the business's stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $7.70, for a transaction totalling $5,890.50. Following the completion of the sale, the insider now directly owns 530,113 shares of the company's stock, valued at $4,081,870.10. Learn More on Donald A. Bergstrom's trading history.
Who are Relay Therapeutics' active insiders?: Relay Therapeutics' insider roster includes Brian Adams (General Counsel), Donald Bergstrom (Insider), Thomas Catinazzo (SVP), and Andy Porter (Insider). Learn More on Relay Therapeutics' active insiders.
Are insiders buying or selling shares of Relay Therapeutics?: In the last twelve months, insiders at the sold shares 16 times. They sold a total of 14,888 shares worth more than $141,512.05. The most recent insider tranaction occured on March, 27th when CFO Thomas Catinazzo sold 348 shares worth more than $2,679.60. Insiders at Relay Therapeutics own 3.5% of the company. Learn More about insider trades at Relay Therapeutics.
Information on this page was last updated on 3/27/2024.

Donald A. Bergstrom Insider Trading History at Relay Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/27/2024	Sell	765	$7.70	$5,890.50	530,113
9/27/2023	Sell	648	$8.38	$5,430.24	238,484
6/27/2023	Sell	647	$12.12	$7,841.64	240,587
12/27/2022	Sell	980	$14.49	$14,200.20	85,886
11/1/2022	Sell	8,000	$22.75	$182,000.00	86,866
10/3/2022	Sell	8,000	$22.43	$179,440.00	88,683
8/24/2022	Sell	15,000	$25.00	$375,000.00	89,659
8/5/2022	Sell	8,000	$20.00	$160,000.00	89,659
7/6/2022	Sell	8,000	$20.00	$160,000.00	91,494
6/24/2022	Sell	8,000	$20.00	$160,000.00	92,493
5/2/2022	Sell	13,000	$24.62	$320,060.00	92,493
4/28/2022	Sell	1,811	$25.57	$46,307.27	92,493
4/1/2022	Sell	18,000	$30.32	$545,760.00	94,304
3/24/2022	Sell	10,000	$30.00	$300,000.00
3/10/2022	Sell	10,000	$25.00	$250,000.00
3/1/2022	Sell	8,000	$23.88	$191,040.00
2/22/2022	Sell	22,994	$20.94	$481,494.36
10/15/2021	Sell	30,000	$34.15	$1,024,500.00
9/27/2021	Sell	646	$36.87	$23,818.02
6/16/2021	Sell	42,242	$33.75	$1,425,667.50	119,483
4/16/2021	Sell	56,324	$32.36	$1,822,644.64	77,241

Donald A. Bergstrom Buying and Selling Activity at Relay Therapeutics

Relay Therapeutics Company Overview

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $6.91

$6.62

$7.00

50 Day Range

MA: $8.84

$6.83

$10.84

2 Week Range

Now: $6.91

$5.95

$18.32

Volume

446,097 shs

Average Volume

1,086,907 shs

Market Capitalization

$906.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63

Trump’s “Tax Free” Retirement Strategy

From Gold Safe Exchange | Ad

Protect your retirement savings from the inevitable devaluation of the dollar…

Donald Bergstrom Biography and Net Worth

What is Donald A. Bergstrom's net worth?

How old is Donald A. Bergstrom?

What is Donald A. Bergstrom's salary?

How do I contact Donald A. Bergstrom?

Has Donald A. Bergstrom been buying or selling shares of Relay Therapeutics?

Who are Relay Therapeutics' active insiders?

Are insiders buying or selling shares of Relay Therapeutics?